Séamus Hussey

Séamus Hussey

Auto-generated profile, based on publicly available information

Séamus Hussey

DOCHAS Group, Children's Health Ireland, University College Dublin Dublin Ireland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2009 in Nature Immunology
Verified
Journal Article
Closed access
LTLeonardo Travassos
Leonardo Travassos
LCLeticia Carneiro
Leticia Carneiro
MRMahendrasingh Ramjeet
Mahendrasingh Ramjeet
SHSeamus Hussey
Seamus Hussey
YKYun-Gi Kim
Yun-Gi Kim
DPDana J Philpott
Dana J Philpott

1 August 2018 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
PDF file
DTDan Turner
Dan Turner
FRFrank M. Ruemmele
Frank M. Ruemmele
EOEsther Orlanski‐Meyer
Esther Orlanski‐Meyer
AGAnne M. Griffiths
Anne M. Griffiths
JCJavier Martin de Carpi
Javier Martin de Carpi
RRRichard K. Russell
Richard K. Russell

1 November 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
FFFiona Fouhy
Fiona Fouhy
CGCaitriona M. Guinane
Caitriona M. Guinane
SHSeamus Hussey
Seamus Hussey
RWRebecca Wall
Rebecca Wall
CRC. Anthony Ryan
C. Anthony Ryan
PCPaul Cotter
Paul Cotter
The infant gut microbiota undergoes dramatic changes during the first 2 years of life. The acquisition and development of this population can be influenced by numerous factors, and antibiotic treatment has been suggested as one of the most significant. Despite this, however, there have been relatively few studies which have investigated the short-term recovery of the infant gut microbiota following antibiotic treatment. The aim of this study was to use high-throughput sequencing (employing both 16S rRNA and rpoB -specific primers) and quantitative PCR to compare the gut microbiota of nine infants who underwent parenteral antibiotic treatment with ampicillin and gentamicin (within 48 h of birth), 4 and 8 weeks after the conclusion of treatment, relative to that of nine matched healthy controls. The investigation revealed that the gut microbiota of the antibiotic-treated infants had significantly higher proportions of Proteobacteria ( P = 0.0049) and significantly lower proportions of Actinobacteria ( P = 0.00001) (and the associated genus Bifidobacterium [ P = 0.0132]) as well as the genus Lactobacillus ( P = 0.0182) than the untreated controls 4 weeks after the cessation of treatment. By week 8, the Proteobacteria levels remained significantly higher in the treated infants ( P = 0.0049), but the Actinobacteria , Bifidobacterium , and Lactobacillus levels had recovered and were similar to those in the control samples. Despite this recovery of total Bifidobacterium numbers, rpoB -targeted pyrosequencing revealed that the number of different Bifidobacterium species present in the antibiotic-treated infants was reduced. It is thus apparent that the combined use of ampicillin and gentamicin in early life can have significant effects on the evolution of the infant gut microbiota, the long-term health implications of which remain unknown.

1 September 2012 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
DTDan Turner
Dan Turner
ALArie Levine
Arie Levine
JEJohanna C. Escher
Johanna C. Escher
AGAnne M. Griffiths
Anne M. Griffiths
RRRichard K. Russell
Richard K. Russell
FRFrank M. Ruemmele
Frank M. Ruemmele

1 August 2018 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
DTDan Turner
Dan Turner
FRFrank M. Ruemmele
Frank M. Ruemmele
EOEsther Orlanski‐Meyer
Esther Orlanski‐Meyer
AGAnne M. Griffiths
Anne M. Griffiths
JCJavier Martin de Carpi
Javier Martin de Carpi
RRRichard K. Russell
Richard K. Russell

1 May 2012 in Gastroenterology
Verified
Journal Article
Open access
PDF file
DRDeepa Raju
Deepa Raju
SHSeamus Hussey
Seamus Hussey
MAMichelle Ang
Michelle Ang
MTMauricio R. Terebiznik
Mauricio R. Terebiznik
MSMichal Sibony
Michal Sibony
NJNicola L. Jones
Nicola L. Jones
Background & Aims The Helicobacter pylori toxin vacuolating cytotoxin (VacA) promotes gastric colonization, and its presence (VacA+) is associated with more-severe disease. The exact mechanisms by which VacA contributes to infection are unclear. We previously found that limited exposure to VacA induces autophagy of gastric cells, which eliminates the toxin; we investigated whether autophagy serves as a defense mechanism against H pylori infection. Methods We investigated the effect of VacA on autophagy in human gastric epithelial cells and primary gastric cells from mice. Expression of p62, a marker of autophagy, was also assessed in gastric tissues from patients infected with toxigenic (VacA+) or nontoxigenic strains. We analyzed the effect of VacA on autophagy in peripheral blood monocytes obtained from subjects with different genotypes of ATG16L1, which regulates autophagy. We performed genotyping for ATG16L1 in 2 cohorts of infected and uninfected subjects. Results Prolonged exposure of human gastric epithelial cells and mouse gastric cells to VacA disrupted induction of autophagy in response to the toxin, because the cells lacked cathepsin D in autophagosomes. Loss of autophagy resulted in the accumulation of p62 and reactive oxygen species. Gastric biopsy samples from patients infected with VacA+, but not nontoxigenic strains of H pylori, had increased levels of p62. Peripheral blood monocytes isolated from individuals with polymorphisms in ATG16L1 that increase susceptibility to Crohn's disease had reduced induction of autophagy in response to VacA+ compared to cells from individuals that did not have these polymorphisms. The presence of the ATG16L1 Crohn's disease risk variant increased susceptibility to H pylori infection in 2 separate cohorts. Conclusions Autophagy protects against infection with H pylori; the toxin VacA disrupts autophagy to promote infection, which could contribute to inflammation and eventual carcinogenesis.